Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1002/gps.1857.
Affiliations
- PMID: 17582225
- DOI: 10.1002/gps.1857
Randomized Controlled Trial
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
Yvonne Freund-Levi et al. Int J Geriatr Psychiatry. 2008 Feb.
Abstract
Background: Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested.
Objective: To determine effects of dietary omega3 supplementation to AD patients with mild to moderate disease on psychiatric and behavioral symptoms, daily functions and a possible relation to APOEgenotype.
Methods: Randomized, double-blind, placebo-controlled clinical trial where 204 AD patients (74+/-9 years) with acetylcholine esterase inhibitor treatment and a MMSE>15 points were randomized to daily intake of 1.7 g DHA and 0.6 g EPA (omega3 group) or placebo for 6 months. Then, all received the omega3 supplementation for 6 more months. Neuropsychiatric symptoms were measured with Neuropsychiatric Inventory (NPI) and Montgomery Asberg Depression Scale (MADRS). Caregivers burden and activities of daily living (Disability Assessment for Dementia, DAD) were also assessed.
Results: One hundred and seventy-four patients fulfilled the trial. 72% were APOEomega4 carriers. No significant overall treatment effects on neuropsychiatric symptoms, on activities of daily living or on caregiver's burden were found. However, significant positive treatment effects on the scores in the NPI agitation domain in APOEomega4 carriers (p=0.006) and in MADRS scores in non-APOEomega4 carriers (p=0.005) were found.
Conclusions: Supplementation with omega3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms (assessed by MADRS) in non-APOEomega4 carriers and agitation symptoms (assessed by NPI) in APOEomega4 carriers. ClinicalTrials.gov identifier: NCT00211159
Copyright (c) 2007 John Wiley & Sons, Ltd.
Similar articles
- Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Freund-Levi Y, et al. Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402. Arch Neurol. 2006. PMID: 17030655 Clinical Trial. - A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
Connelly PJ, Prentice NP, Cousland G, Bonham J. Connelly PJ, et al. Int J Geriatr Psychiatry. 2008 Feb;23(2):155-60. doi: 10.1002/gps.1856. Int J Geriatr Psychiatry. 2008. PMID: 17600848 Clinical Trial. - Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group. Feldman H, et al. Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69. doi: 10.1002/gps.1325. Int J Geriatr Psychiatry. 2005. PMID: 15920715 Clinical Trial. - Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT. Beier MT. Pharmacotherapy. 2007 Mar;27(3):399-411. doi: 10.1592/phco.27.3.399. Pharmacotherapy. 2007. PMID: 17316151 Review.
Cited by
- Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.
Dacks PA, Shineman DW, Fillit HM. Dacks PA, et al. J Nutr Health Aging. 2013 Mar;17(3):240-51. doi: 10.1007/s12603-012-0431-3. J Nutr Health Aging. 2013. PMID: 23459977 - Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood.
Muldoon MF, Ryan CM, Sheu L, Yao JK, Conklin SM, Manuck SB. Muldoon MF, et al. J Nutr. 2010 Apr;140(4):848-53. doi: 10.3945/jn.109.119578. Epub 2010 Feb 24. J Nutr. 2010. PMID: 20181791 Free PMC article. - Effects of N-3 Polyunsaturated Fatty Acids on Dementia.
Yanai H. Yanai H. J Clin Med Res. 2017 Jan;9(1):1-9. doi: 10.14740/jocmr2815w. Epub 2016 Nov 24. J Clin Med Res. 2017. PMID: 27924168 Free PMC article. Review. - Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review.
Lee JY, Wong CY, Koh RY, Lim CL, Kok YY, Chye SM. Lee JY, et al. Yale J Biol Med. 2024 Jun 28;97(2):205-224. doi: 10.59249/JNKB9714. eCollection 2024 Jun. Yale J Biol Med. 2024. PMID: 38947104 Free PMC article. Review. - Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation.
Narendran R, Frankle WG, Mason NS, Muldoon MF, Moghaddam B. Narendran R, et al. PLoS One. 2012;7(10):e46832. doi: 10.1371/journal.pone.0046832. Epub 2012 Oct 3. PLoS One. 2012. PMID: 23056476 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials